Improving OS in MCL

An observational study was undertaken by the Nordic Lymphoma Group to determine the efficacy of different first-line therapies in patients with mantle cell lymphoma (MCL).


Data were gathered from the Danish and Swedish Lymphoma Registries for the period of 2000 to 2011. Patients (n = 1,389) were diagnosed with MCL with the median age of diagnosis being 71 years. Among those who received systemic therapy, both rituximab (n = 766; HR = 0.66; p = 0.001) and autologous stem cell transplant (n = 273; HR = 0.55, p = 0.004) were associated with improved overall survival (OS). Patients (n = 43) with stage II-III who received radiotherapy with curative intent showed a three-year OS of 93%. For more information, click here.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe


Have you ever attended a meeting with a lymphoma support group?




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.